Clorox (NYSE:CLX) was upgraded by investment analysts at Argus from a “hold” rating to a “buy” rating in a research note issued on Tuesday, The Fly reports.

CLX has been the subject of several other reports. Atlantic Securities initiated coverage on Clorox in a research note on Thursday, September 20th. They set a “neutral” rating and a $151.00 price objective for the company. Goldman Sachs Group lowered Clorox from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $127.00 to $112.00 in a research note on Tuesday, July 17th. They noted that the move was a valuation call. Bank of America increased their price objective on Clorox from $130.00 to $140.00 and gave the stock a “neutral” rating in a research note on Monday, July 16th. ValuEngine upgraded Clorox from a “sell” rating to a “hold” rating in a research note on Tuesday, June 26th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $153.00 price objective on shares of Clorox in a research note on Friday, August 3rd. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $131.79.

Clorox stock opened at $149.95 on Tuesday. The company has a debt-to-equity ratio of 3.15, a current ratio of 1.09 and a quick ratio of 0.67. Clorox has a 52-week low of $113.57 and a 52-week high of $153.38. The firm has a market cap of $19.47 billion, a price-to-earnings ratio of 23.95, a P/E/G ratio of 3.16 and a beta of 0.35.

Clorox (NYSE:CLX) last released its quarterly earnings data on Thursday, August 2nd. The company reported $1.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.08. Clorox had a return on equity of 103.18% and a net margin of 13.44%. The firm had revenue of $1.69 billion during the quarter, compared to analyst estimates of $1.72 billion. During the same period in the prior year, the company posted $1.53 earnings per share. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. equities analysts anticipate that Clorox will post 6.41 EPS for the current fiscal year.

In related news, SVP Michael R. Costello sold 9,265 shares of the firm’s stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $140.02, for a total value of $1,297,285.30. Following the transaction, the senior vice president now owns 34,293 shares in the company, valued at $4,801,705.86. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Linda J. Rendle sold 382 shares of the firm’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $148.32, for a total value of $56,658.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,268 shares of company stock worth $4,196,686. 1.00% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of CLX. Neuberger Berman Group LLC boosted its holdings in Clorox by 6.4% in the first quarter. Neuberger Berman Group LLC now owns 31,135 shares of the company’s stock valued at $4,192,000 after acquiring an additional 1,868 shares during the last quarter. Toronto Dominion Bank lifted its stake in Clorox by 25.5% in the first quarter. Toronto Dominion Bank now owns 69,724 shares of the company’s stock valued at $9,278,000 after buying an additional 14,176 shares during the period. Great West Life Assurance Co. Can lifted its stake in Clorox by 6.3% in the first quarter. Great West Life Assurance Co. Can now owns 251,570 shares of the company’s stock valued at $33,541,000 after buying an additional 14,914 shares during the period. Norinchukin Bank The lifted its stake in Clorox by 15.0% in the first quarter. Norinchukin Bank The now owns 11,858 shares of the company’s stock valued at $1,578,000 after buying an additional 1,550 shares during the period. Finally, Fisher Asset Management LLC lifted its stake in Clorox by 160.3% in the first quarter. Fisher Asset Management LLC now owns 31,811 shares of the company’s stock valued at $4,234,000 after buying an additional 19,589 shares during the period. Institutional investors and hedge funds own 78.07% of the company’s stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Recommended Story: How Do Tariffs Affect Trade Balances?

The Fly

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.